[Topical BCG therapy of in situ cancer of the urinary bladder].
Ten patients with primary, secondary and concurrent Tis were treated by intravesically instilled BCG-solution. A complete tumor remission could be obtained in 6 patients. Local toxicity was the reason for discontinuing the treatment in 2 patients. One patient developed a granulomatous prostatitis during the treatment. Although significant side effects did occur we think that topical BCG therapy is an effective treatment modality in Tis of the urinary bladder.
D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000009:adverse effects / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D001500:BCG Vaccine
Topische BCG-Therapie des In-situ-Karzinoms der Harnblase.